HUMIRA (adalimumab), TNFα inhibitor

• HUMIRA now has marketing authorisation in the treatment of severe chronic plaque psoriasis in children from 4 years of age and adolescents and in the case of insufficient response to a topical treatment and to phototherapy or when these treatments are inappropriate.
• It should be reserved for treatment of severe chronic plaque psoriasis defined by:

            - failure (insufficient response, contraindication or intolerance) to at least two treatments including nonbiologic systemic treatments and phototherapy

            - an extensive form and/or substantial psychosocial impact.

• The safety profile of adalimumab is similar in adults, children and adolescents.